Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target

Leerink Partners maintained their Outperform rating on Celldex Therapeutics's stock with a price target of $88.00.The price target implies an upside of 162.6% from the Sep 22 close of $33.51.Key takeaways from the analyst noteStrong Clinical Efficacy: Celldex Therapeutics' lead product candidate, b…